Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Kilitch Drugs (India) Ltd (KILITCH)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524500 NSE: KILITCH Pharmaceuticals & Drugs | Small Cap | Kilitch Drugs(India) Share Price
₹178.55 -9.35 (-4.98%)
As on 14-Aug'26 16:59
Kilitch Drugs (India) Ltd (KILITCH)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524500 NSE: KILITCH Pharmaceuticals & Drugs | Small Cap | Kilitch Drugs(India) Share Price
₹178.55 -9.35 (-4.98%)
As on 14-Aug'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹624 Cr.
Current Price
₹178.6
52-Week Low / High
₹121 / 220
TTM EPS
₹9.3
TTM Sales
₹195 Cr.
Book Value per Share
₹96.6
P/E Ratio
19.12
Lower than its 5-year historical median
Industry PE
53.5
Price to Book (P/B)
1.85
In line with its 5-year historical median
Price to Sales (P/S)
3.20
Lower than its 5-year historical median
EV/EBITDA
14.81
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
11.07%
Outperforms industry median
Return on Capital Employed (ROCE)
12.37%
Outperforms industry median
Return on Assets (ROA)
7.62%
Operating Profit Margin
17.6%
Net Profit Margin
17.18%
Gross Profit Margin
23.3%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
3.84%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
6.56%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
3.98%
Asset Quality
Promoter Holding
63.77%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹303 Cr.
Equity
₹35 Cr.
Face Value
₹10
All Time Low / High
₹0.37 / 245.00
Check Before You Invest
Quality
Not GoodValuation
Somewhat OvervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Kilitch Drugs (India) Ltd a good quality company?
Kilitch Drugs (India) Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Kilitch Drugs (India) Ltd performance compare with that of its Peers?
Revenue growth of Kilitch Drugs (India) Ltd vs industry peers?
Kilitch Drugs (India) Ltd revenue CAGR is 21.91%, compared to the industry median CAGR of 5.75%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Kilitch Drugs (India) Ltd?
Promoters hold 63.77% of the Kilitch Drugs (India) Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Kilitch Drugs (India) Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 26.8% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Kilitch Drugs (India) Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -0.3% | 6% | 13.8% | 3.8% | 4.9% | 7.8% | 9.9% | 10.8% | 15.5% | 12.4% | - |
| Value Creation Index ⓘ | -1.0 | -0.6 | 0.0 | -0.7 | -0.7 | -0.4 | -0.3 | -0.2 | 0.1 | -0.1 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 28.1 | 50.5 | 96.4 | 60.8 | 70 | 105 | 118 | 132 | 182 | 189 | 195 |
| Sales YoY Gr. | - | 79.3% | 91.1% | -37% | 15.2% | 50.2% | 12% | 11.7% | 38% | 3.8% | - |
| Adj EPS ⓘ | 0.1 | 1.8 | 4.1 | 0.7 | 1.5 | 2.9 | 4.4 | 4.6 | 7.5 | 7.3 | 9.3 |
| YoY Gr. | - | 1358.3% | 136.6% | -84.1% | 121.2% | 101.4% | 49% | 4.8% | 63.2% | -3.2% | - |
| BVPS (₹) ⓘ | 43.5 | 45.4 | 47.8 | 47.7 | 51.3 | 55 | 59.8 | 67.7 | 76.9 | 95.2 | 96.6 |
| Adj Net Profit ⓘ | 0.3 | 4.9 | 13 | 2.1 | 4.6 | 9.4 | 13.9 | 15.1 | 24.6 | 25.4 | 33 |
| Cash Flow from Ops. ⓘ | 0.6 | -1.3 | 7.4 | 7.3 | 6.1 | 5.2 | 6.1 | -2.6 | 15.2 | 12.3 | - |
| Debt/CF from Ops. ⓘ | 1.1 | -0.6 | 1.3 | 1.7 | 2.4 | 3.9 | 3.6 | -12.1 | 3.2 | 7.2 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 23.5% | 21.9% | 17% | 3.8% | ||||
| Adj EPS ⓘ | 57.7% | 37.8% | 18.3% | -3.2% | ||||
| BVPSⓘ | 9.1% | 13.1% | 16.7% | 23.8% | ||||
| Share Price | 26.8% | 13.7% | 25.2% | -17.4% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0.3 | 3.9 | 9.2 | 1.4 | 3 | 5.5 | 7.5 | 7.2 | 10.4 | 8.7 | 9.7 |
| Op. Profit Mgn % ⓘ | 0.5 | 11.1 | 17 | 1.9 | 7.6 | 11.3 | 14.7 | 15.5 | 17.1 | 17.6 | 17.2 |
| Net Profit Mgn % ⓘ | 1.2 | 9.8 | 13.5 | 3.4 | 6.6 | 8.9 | 11.8 | 11.5 | 13.6 | 13.5 | 16.7 |
| Debt to Equity ⓘ | 0 | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.3 | - |
| Working Cap Days ⓘ | 280 | 193 | 173 | 373 | 364 | 299 | 314 | 319 | 285 | 349 | 180 |
| Cash Conv. Cycle ⓘ | 163 | 86 | 64 | 107 | 59 | 39 | 32 | 55 | 58 | 47 | 101 |
Valuation of Kilitch Drugs(India) - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 28 | 50 | 96 | 61 | 70 | 105 | 118 | 132 | 182 | 189 |
| Operating Expenses ⓘ + | 29 | 45 | 81 | 60 | 65 | 94 | 100 | 111 | 150 | 155 |
| Operating Profit ⓘ | -1 | 6 | 16 | 1 | 5 | 11 | 17 | 20 | 31 | 33 |
| Operating Profit Margin (%) | -2.0% | 11.1% | 16.2% | 1.9% | 7.6% | 10.6% | 14.7% | 15.5% | 17.1% | 17.6% |
| Other Income ⓘ + | 2 | 3 | 6 | 6 | 4 | 5 | 5 | 6 | 14 | 14 |
| Interest ⓘ | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 |
| Depreciation ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit Before Tax ⓘ | -0 | 7 | 20 | 5 | 8 | 14 | 19 | 23 | 41 | 42 |
| Tax ⓘ | -0 | 1 | 5 | 1 | 1 | 3 | 4 | 6 | 10 | 9 |
| Profit After Tax | -0 | 6 | 15 | 4 | 6 | 11 | 16 | 18 | 31 | 32 |
| PAT Margin (%) | -0.1% | 12.3% | 15.3% | 7.3% | 8.8% | 10.0% | 13.3% | 13.4% | 17.2% | 17.2% |
| Adjusted EPS (₹) | -0.0 | 2.2 | 4.7 | 1.4 | 1.9 | 3.3 | 4.9 | 5.4 | 9.5 | 9.3 |
| Dividend Payout Ratio (%) | 0% | 11.10% | 5.20% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 118 | 127 | 150 | 150 | 163 | 175 | 191 | 223 | 253 | 333 | |
| Debt + | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 31 | 49 | 88 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 6 | 8 | 5 | 8 | 14 | 28 | 29 | 26 | 47 | 68 | |
| Others Liabilities ⓘ | 4 | 8 | 6 | 2 | 4 | 8 | 9 | 5 | 6 | 6 | |
| Total Liabilities ⓘ | 128 | 144 | 171 | 173 | 195 | 231 | 250 | 285 | 355 | 495 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 8 | 7 | 8 | 8 | 7 | 14 | 15 | 16 | 20 | 20 | |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 47 | 140 | |
| Investments ⓘ | 96 | 101 | 100 | 98 | 107 | 117 | 110 | 121 | 121 | 124 | |
| Inventories | 3 | 3 | 5 | 6 | 4 | 5 | 2 | 4 | 15 | 12 | |
| Trade Receivables | 15 | 21 | 23 | 17 | 23 | 41 | 53 | 62 | 83 | 117 | |
| Cash Equivalents | 2 | 4 | 4 | 3 | 6 | 2 | 18 | 19 | 7 | 10 | |
| Others Assets ⓘ | 4 | 9 | 32 | 42 | 49 | 50 | 51 | 58 | 61 | 72 | |
| Total Assets ⓘ | 128 | 144 | 171 | 173 | 195 | 231 | 250 | 285 | 355 | 495 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 1 | -1 | 7 | 7 | 6 | 5 | 6 | -3 | 15 | 12 |
| Cash Flow From Investing Activity ⓘ + | -1 | -2 | -22 | -10 | -5 | -16 | 6 | -9 | -41 | -96 |
| Cash Flow From Financing Activity ⓘ + | -0 | 6 | 15 | 1 | 2 | 8 | 3 | 11 | 16 | 86 |
| Net Cash Flow ⓘ | -0 | 2 | 0 | -1 | 3 | -3 | 15 | 0 | -11 | 2 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -0.03 | 5.06 | 10.65 | 2.97 | 3.93 | 6.23 | 8.59 | 8.51 | 13.11 | 11.07 |
| ROCE (%) | -0.26 | 6.01 | 13.79 | 3.79 | 4.91 | 7.83 | 9.9 | 10.75 | 15.49 | 12.37 |
| Asset Turnover Ratio | 0.22 | 0.37 | 0.61 | 0.35 | 0.38 | 0.49 | 0.49 | 0.49 | 0.57 | 0.44 |
| PAT to CFO Conversion(x) | N/A | -0.17 | 0.47 | 1.75 | 1 | 0.45 | 0.38 | -0.17 | 0.48 | 0.38 |
| Working Capital Days | ||||||||||
| Receivable Days | 200.60 | 127.40 | 83 | 120.50 | 103.80 | 111.70 | 146.50 | 159.40 | 145.90 | 194.20 |
| Inventory Days | 33.80 | 19.40 | 14.20 | 30.80 | 23.80 | 14.90 | 10.90 | 8.40 | 19.40 | 26 |
| Payable Days | 150.10 | 93.60 | 45.20 | 68.30 | 100.30 | 125.20 | 176.60 | 151.60 | 145.90 | 237.40 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Kilitch Drugs (India) Ltd FAQs
The current trading price of Kilitch Drugs(India) on 14-Aug-2026 16:59 is ₹178.6.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 13-Aug-2026 the market cap of Kilitch Drugs(India) stood at ₹624.2 Cr
The latest P/E ratio of Kilitch Drugs(India) as of 13-Aug-2026 is 19.12.
The latest P/B ratio of Kilitch Drugs(India) as of 13-Aug-2026 is 1.85.
The 52-week high of Kilitch Drugs(India) is ₹219.7 and the 52-week low is ₹121.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kilitch Drugs(India) is ₹195 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kilitch Drugs (India) Ltd is a below average quality company.
The key valuation ratios of Kilitch Drugs (India) Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Kilitch Drugs (India) Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Kilitch Drugs (India) Ltd
Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.
Kilitch is one of the largest manufacturers of antibacterial parenteral formulations. It is also one of the largest producers of sterile liquid formulations in small volumes in India. Kilitch also boasts of 25 years of quality contract manufacturing service to reputed national and multinational pharmaceutical companies. its sound knowledge about the industry has resulted in the growth of the organizations along with them as a leading contract manufacturing company in the country.
Keeping pace with the increasing demand of its clients for contract manufacturing, Kilitch has added 2 dedicated blocks and is in the process of adding another 3 dedicated fully USFDA / UKMHRA compliant manufacturing facility in Paonta Sahib (North India). All its plants are approved by the local as well as World Health Organization (WHO) for GMP standards. Kilitch has 3 manufacturing facilities spread across India.
Kilitch has over 25 years of experience in product development and manufacturing. It offers a wide spectrum of contract services, providing reliable supply, scientific expertise and bottom line results to meet the development, clinical and commercial outsourcing needs. Kilitch has been engaged in successful tie-ups with over 20 leading pharmaceutical companies -- Ranbaxy Laboratories Limited, Sandoz India Limited, Zydus Cadila, Nicholas Piramal India Limited, USV Limited, Merck Limited to name a few.
In 2010 the company listed its Equity Shares at NSE.
DCGI Approval-- The company has received the DCGI approvals for Ceftriaxone+Tazobactam, Ceftriaxone+Salbactam,Cefipime +Tazobactam and awaiting for approval for the following products, Rabeprazole, Ceftazidime+Tazobactam, Cefoperazone+Tazobactam
Product range of the company includes- Carbapenems, Cephalosporins, Beta - Lactam Antibiotics, Steroids & Hormones, Gastrology, Gastrology, NSAIDs, Anti Malarials
Kilitch has signed an agreement with a US-based pharmaceutical company for manufacturing of its generic molecules for the period of 2 year which started in mid 2008 and would like to expand their business thereon.
Clientele: Sandoz, Ranbaxy, Emcure, Nicholas, Ajanta pharma, Zuventas, Zydus Cadilla, USV, Flamingo Pharma and many others.
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
